Targets › ASXL3
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout May 2027.
Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. (UniProt, Q9C0F0)
Open in Phaseline: the race on ASXL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| n-Lorem Foundation | nL-ASXL3-001 Antisense oligonucleotide targeting ASXL3 nonsense variant | ASXL3 | Phase 1 | Bainbridge-Ropers Syndrome | May 2027 |
Bainbridge-Ropers Syndrome (1)
small molecule (1)
n-Lorem Foundation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.